StockData
Nyxoah SA logo

Nyxoah SA (NYXH) stock

NYXHNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 26, 2026Score 1/30
$0.86−0.04 (-4.10%)

Close on Nov 18, 2026Market cap $37.13MP/E –Yield –

Nyxoah r&d expenses

Research and development expenses are spending on new products and technology.

Nyxoah's R&D Expenses for the twelve months ending Dec 31, 2022 was €15.86M, up 28.5% year over year. For fiscal 2025 it was €42.82M, up 24.8% from the year before. The highest annual figure on record is €42.82M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025€42.82M+24.8%
FY2024Dec 31, 2024€34.33M+28.8%
FY2023Dec 31, 2023€26.65M+68.0%
FY2022Dec 31, 2022€15.86M+28.5%
FY2021Dec 31, 2021€12.34M+428.4%
FY2020Dec 31, 2020€2.34M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026€9.54M+108.6%
Q2 FY2025Jun 30, 2025€10.06M+138.3%
Q2 FY2024Jun 30, 2024€7.47M+115.3%
Q2 FY2023Jun 30, 2023€6.61M+98.1%
Q4 FY2022Dec 31, 2022€4.58M+30.1%
Q3 FY2022Sep 30, 2022€4.22M–
Q2 FY2022Jun 30, 2022€3.47M–
Q4 FY2021Dec 31, 2021€3.34M–
Q3 FY2021Sep 30, 2021€3.52M–

More Nyxoah figures

See a number that looks wrong?